September 23, 2025Clinical and Applied Thrombosis/HemostasisOpen Access

Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A

View Full Paper

Ask AI

Bookmark

Efmoroctocog alfa effectively supported surgical procedures in pediatric patients with hemophilia A.
Eighteen male patients with severe FVIII deficiency averaged 8.4 years, all successfully treated with Ealfa.
The retrospective observational study indicates extended half-life FVIII may optimize treatment outcomes over standard products.
Surgical interventions included dental extractions and fracture repair, demonstrating the treatment's safety in complex cases.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study reveals effective surgical management with efmoroctocog alfa in pediatric hemophilia A, suggesting improved prophylaxis with extended half-life FVIII products.

Cite This Study

Solğun et al. (2025) studied this question.

synapsesocial.com/papers/68d43edd713b0b5dfea7e69e https://doi.org/10.1177/10760296251377646

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals effective surgical management with efmoroctocog alfa in pediatric hemophilia A, suggesting improved prophylaxis with extended half-life FVIII products.

Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A

Key Points

Discussion

Implication

Cite This Study

Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading